Microarray of CD11b+CD11c–Ly6Chi inflammatory monocytes in tumor tissue and spleens from Th9 treated mice

We recently reported that tumor-specific Th9 cells are less susceptible to exhaustion, fully cytolytic to tumor cells, and possess long-term persistence capacity because of their unique hyperproliferative T cell feature. However, these observations only revealed how tumor-specific Th9 cells eradicate antigen-positive tumor cells. Given the unmet need to develop effective ACT strategies with tumor-specific Th9 cells for solid tumors with the heterogeneity in antigen expression, the CD11b+CD11c–Ly6Chi inflammatory monocytes were flow-sorted from Th9 treated mice, and been further analyzed for microarray. Mice were treated with Th9 cells, and 10 days after Th9 transfer, tumor tissue and spleens were harvested and dissociated for cell sorting. CD11b+CD11c–Ly6Chi inflammatory monocytes were flow-sorted. Total RNA was extracted with the RNeasy Mini kit (Qiagen)